Company Mirna Therapeutics Inc Nasdaq
Equities
US60470J1034
Biotechnology & Medical Research
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Synthetic Biology Therapeutics
100.0
%
| 1 | 100.0 % | 3 | 100.0 % | +185.68% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 1 | 100.0 % | 3 | 100.0 % | +185.68% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Mary Dooley
DFI | Director of Finance/CFO | 43 | 18-05-31 |
Caroline Kurtz
PRN | Corporate Officer/Principal | - | 16-09-30 |
Brendan St Amant
LAW | General Counsel | - | 21-06-30 |
Thomas J. Adam
HRO | Human Resources Officer | - | 17-08-27 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Richard Shea
BRD | Director/Board Member | 72 | 17-08-27 |
Peter Barrett
CHM | Chairman | 71 | 17-08-27 |
Director/Board Member | 64 | 12-09-30 | |
Director/Board Member | 59 | 20-12-07 | |
Nick Leschly
BRD | Director/Board Member | 51 | 17-08-27 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 11,986,803 | 9,884,522 ( 82.46 %) | 279,792 ( 2.334 %) | 82.46 % |
Company contact information
![address Mirna Therapeutics Inc](https://cdn.zonebourse.com/static/address/23894470.png)
Sector
1st Jan change | Capi. | |
---|---|---|
+23.50% | 45.01B | |
+47.19% | 40.96B | |
-5.16% | 38.62B | |
+36.37% | 32.6B | |
-7.79% | 27.49B | |
+18.06% | 27.17B | |
+47.29% | 14.61B | |
+41.91% | 12.95B | |
-1.02% | 11.36B |